P383: USING CF-DNA AS STARTING MATERIAL FOR MRD STUDIES BY NGS IMPROVES THE SENSITIVITY OF THE METHOD AGAINST CTCS.

• N. Álvarez Sánchez-Redondo,
• S. Dorado,
• A. Martín,
• L. Rufián,
• V. Garrido,
• A. Giménez,
• L. Moreno,
• Y. Heredia,
• J. Martínez-López,
• S. Barrio,
• R. Ayala

Affiliations

N. Álvarez Sánchez-Redondo

1 1. Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC

S. Dorado

2 3.Computer Science and 4.Altum Sequencing Co., Madrid, Spain. Engineering Department. Carlos III University, Madrid and

A. Martín

3 4.Altum Sequencing Co., Madrid, Spain.

L. Rufián

1 1. Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC

V. Garrido

1 1. Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC

A. Giménez

1 1. Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC

L. Moreno

1 1. Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC

Y. Heredia

4 4. Altum Sequencing Co., Madrid, Spain.

J. Martínez-López

5 1.Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, and 2.Complutense University of Madrid

S. Barrio

6 1.Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, and 4.Altum Sequencing Co., Madrid, Spain.

R. Ayala

7 1.Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, and 2.Complutense University of Madrid., Madrid, Spain